Anand Sharma to Combined Modality Therapy
This is a "connection" page, showing publications Anand Sharma has written about Combined Modality Therapy.
Connection Strength
0.856
-
Cervical esophageal cancer: a population-based study. Head Neck. 2015 Jun; 37(6):808-14.
Score: 0.095
-
A rare occurrence of biphasic pulmonary blastoma in an elderly male. Anticancer Res. 2013 Sep; 33(9):3911-5.
Score: 0.090
-
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Jpn J Clin Oncol. 2011 Mar; 41(3):334-42.
Score: 0.074
-
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9.
Score: 0.073
-
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52.
Score: 0.072
-
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun; 28(5):340-8.
Score: 0.072
-
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. 2010 Feb; 120(2):236-42.
Score: 0.070
-
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502.
Score: 0.066
-
Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1108-13.
Score: 0.065
-
Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck Cancer. JCO Oncol Pract. 2021 10; 17(10):e1512-e1523.
Score: 0.038
-
Barriers to the Delivery of Timely, Guideline-Adherent Adjuvant Therapy Among Patients With Head and Neck Cancer. JCO Oncol Pract. 2020 12; 16(12):e1417-e1432.
Score: 0.036
-
Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. Cancer. 2017 Dec 15; 123(24):4841-4850.
Score: 0.030
-
Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008 Jul; 118(7):1180-5.
Score: 0.016
-
Laryngeal penetration and aspiration during swallowing after the treatment of advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2005 Jul; 131(7):615-9.
Score: 0.013
-
Management of paranasal sinus malignancy. Curr Treat Options Oncol. 2005 Jan; 6(1):3-18.
Score: 0.012
-
Melanoma of the head and neck. Curr Treat Options Oncol. 2005 Jan; 6(1):19-30.
Score: 0.012
-
Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation. Radiother Oncol. 2004 Nov; 73(2):233-6.
Score: 0.012
-
Oral cancer treatment. Curr Treat Options Oncol. 2003 02; 4(1):27-41.
Score: 0.011